What is Personalis, Inc. (PSNL) stock price today?

Personalis, Inc. (PSNL) is currently trading at $16.00, down 0.37% today.

What is PSNL P/E ratio?

Personalis, Inc.'s P/E ratio is -14.94. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is PSNL return on equity (ROE)?

Personalis, Inc.'s return on equity (ROE) is -46.47%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Personalis, Inc.'s market cap?

Personalis, Inc. has a market capitalization of $1.71B.

NASDAQ · Medical - Diagnostics & Research

Personalis, Inc. (PSNL) Stock

$16.00 -0.37% NASDAQ: PSNL Healthcare

Valuation

Metric	Value
Price	$16.00
Market Cap	$1.71B
P/E Ratio	-14.94
P/B Ratio	7.30
P/S Ratio	24.95
EPS (TTM)	$-0.91
52-Week High	$18.89
52-Week Low	$4.96
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-46.47%
ROA	-34.34%
ROCE	-43.01%
Gross Margin	13.72%
Operating Margin	-1.59%
Net Margin	-153.84%
Debt/Equity	0.16
Current Ratio	6.70

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$85.0M	$65.0M	$73.0M	$85.0M	$70.0M
Operating Profit	$-65.0M	$-116.0M	$-96.0M	$-68.0M	$-88.0M
Net Profit	$-65.0M	$-113.0M	$-108.0M	$-81.0M	$-81.0M
EPS	$-1.49	$-2.48	$-2.25	$-1.37	$-0.91
Op Margin	-76.4%	-177.6%	-131.1%	-80.7%	-126.4%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$397.0M	$293.0M	$225.0M	$270.0M	$334.0M
Total Liabilities	$86.0M	$75.0M	$96.0M	$67.0M	$73.0M
Cash	$106.0M	$89.0M	$57.0M	$91.0M	$124.0M
Borrowings	$58.0M	$49.0M	$48.0M	$44.0M	$40.0M

Latest News

Tempus AI (TEM) On Its Personalis Deal And Whether The Bull Case Is Priced In Simply Wall St. · Jul 22, 2026 Tempus AI acquires cancer-monitoring firm Personalis for $1.5 billion Quartz · Jul 21, 2026 Tempus AI acquires Personalis in $1.5bn precision oncology-focused deal Medical Device Network · Jul 21, 2026 Tempus AI (TEM) Is Buying Personalis For $1.5 Billion To Deepen Cancer Monitoring Simply Wall St. · Jul 21, 2026 Tempus AI Buys Personalis in $1.7 Billion Precision Oncology Deal GuruFocus.com · Jul 20, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-71.0M	$-70.0M	$-56.0M	$-45.0M	$-75.0M
Investing Cash Flow	$-71.0M	$3.0M	$2.0M	$-37.0M	$-27.0M
Financing Cash Flow	$4.0M	$0	$7.0M	$18.0M	$0
Net Cash Flow	$39.0M	$-16.0M	$-32.0M	$34.0M	$33.0M
Free Cash Flow	$-82.0M	$-120.0M	$-67.0M	$-47.0M	$-79.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-3.93
EV / EBITDA	-17.30
FCF Yield	-5.81%
Quick Ratio	5.08
Interest Coverage	-536.66
Return 1Y	80.77%
Return 3Y	465.74%
Return 5Y	-28.43%

Ownership

Insiders Held26.16%

Institutions Held66.94%

Institutions Float Held90.66%

Institutional Holder	Shares	Report Date
Merck & Co., Inc.	14,044,943	2026-03-31
Lightspeed Management Company, L.L.C.	8,160,734	2026-03-31
ARK Investment Management, LLC	7,944,112	2026-03-31
Ameriprise Financial, Inc.	7,592,807	2026-03-31
Blackrock Inc.	5,389,885	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BLLNBillionToOne, Inc.	$98.09	+2.81%	154.24	$4.51B	0.00%
BNRBurning Rock Biotech Limited	$11.30	-3.42%	-1.36	$11.94M	0.00%
FLGTFulgent Genetics, Inc.	$21.74	+4.42%	-7.62	$617.43M	0.00%
GHGuardant Health, Inc.	$167.47	+1.15%	-48.23	$22.47B	0.00%
GRALGRAIL, Inc.	$140.58	+6.01%	-14.69	$6.03B	0.00%

About Personalis, Inc.

Personalis, Inc. is led by CEO Christopher Hall, employs 228 people, headquartered in US, publicly traded since 2019.

Personalis, Inc. (PSNL) stock trades at $16.00 with a market capitalization of $1.71B. The stock is valued at a price-to-earnings (P/E) ratio of -14.94, price-to-book of 7.30, price-to-sales of 24.95. Over the past 52 weeks the stock has ranged between $4.96 and $18.89, and currently trades 15.3% below its 52-week high.

On profitability, Personalis, Inc. generates a return on equity (ROE) of -46.47%, return on capital employed of -43.01%, an operating margin of -1.59%, a net profit margin of -153.84%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides